Labeling of Disease-Modifying Therapies for Neurodegenerative Disorders

Frontiers in Medicine - Switzerland
doi 10.3389/fmed.2019.00223
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

Frontiers Media SA

Related search

Promising Disease-Modifying Therapies for Parkinson’s Disease

Science Translational Medicine
Medicine
2019English

Neurodegenerative Disease: Two–for–one on Potential Therapies

Nature
Multidisciplinary
2017English

Disease-Modifying Therapies in Relapsing–remitting Multiple Sclerosis

Neuropsychiatric Disease and Treatment
PsychiatryMental HealthBiological Psychiatry
2010English

Mesenchymal Stromal Cell Therapies for Neurodegenerative Diseases

Mayo Clinic Proceedings
Medicine
2019English

Therapeutic Opportunities for Caffeine in Alzheimer's Disease and Other Neurodegenerative Disorders

Journal of Alzheimer's Disease
GerontologyClinical PsychologyMental HealthPsychiatryGeriatricsMedicineNeuroscience
2010English

Price Analysis of Multiple Sclerosis Disease-Modifying Therapies Marketed in the US

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Database of Neurodegenerative Disorders

Bioinformation
2007English

Pnd131 - Patient Preferences for Different Modes and Frequency of Administration of Multiple Sclerosis Disease Modifying Therapies

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Psychiatric Disorders: Neurodevelopmental Disorders, Neurodegenerative Disorders, or Both?

Dialogues in Clinical Neuroscience
PsychiatryBiological PsychiatryMental Health
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy